Could a cancer drug boost social abilities in rare genetic condition?
NCT ID NCT07218575
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether everolimus, a drug already approved for other conditions, can safely improve social abilities in people with PTEN Hamartoma Tumor Syndrome (PHTS). About 60 adults and children with PHTS and social difficulties will take either everolimus or a placebo for 6 months, then all will receive everolimus for another 6 months. The goal is to see if the drug helps with social skills and functioning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus (Afinitor, Zortress)
What this could lead to
If it works, this could point toward a treatment for social difficulties in people with PTEN Hamartoma Tumor Syndrome.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drug may not improve social abilities, and side effects from everolimus are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COWDEN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stanford University
Stanford, California, 94305, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••